Lung cancer stage distribution from before COVID-19 through 18 Months of the pandemic: The experience of a large-volume oncological referral centre

Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19

Résumé en anglais

The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has caused global lockdowns with severe mobility restrictions and social isolation measures to contain the epidemic. COronaVIrus Disease 19 (COVID-19) has put unprecedented tests and strain on the resilience of global healthcare systems, resulting in the unavoidable deprioritisation of oncological activities [1,2]. Numerous centres have implemented stringent measures to minimise the risk of exposure to cancer patients. However, the benefits of these actions must be weighed against the costs, as COVID-19 should also be held accountable for future worsened oncological survival outcomes. Surprisingly, the most relevant risk factors of COVID-19 severity in lung cancer patients were not cancer or cancer-directed therapies but lung cancer risk factors and associated chronic medical conditions [3].